CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Ananda Pharma PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Ananda Pharma PLC
6th Fl
Allianz House, 60 Gracechurch Street
LONDON, EC3V 0HR  United Kingdom Ticker: ANAANA
Business Summary
Ananda Pharma plc, formerly Ananda Developments plc, is a United Kingdom-based pharmaceutical company. The Company is focused on the research and development of cannabidiol (CBD)-based therapies. It is engaged in developing medicines for the treatment of drug-resistant epilepsies and specific inflammatory pain conditions (starting with chemotherapy induced peripheral neuropathy (CIPN) & endometriosis) and Heart Failure with preserved Ejection Fraction (HFpEF). ACTiON is a Phase II, double blind placebo-controlled crossover randomized clinical trial (RCT) to assess its MRX1 drug candidate versus placebo in the treatment of CIPN. ENDOCAN-1 shall help determining whether a cannabinoid can reduce endometriosis-associated pain. HFpEF is a study designed to evaluate the cardioprotective effects of its MRX1 drug candidate in a preclinical HFpEF model. Its two novel cannabinoid medicines: MRX2 (CBD) and MRX2T, helps in a range of seizure types and epilepsies in children and adults.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
7/31/20241/31/2024Yes----

Industries
SIC Code Description
6282 Investment advice
6799 Investors, not elsewhere classified
6289 Services allied with the exchange of securities or commodities

General Information
Number of Employees: 5 (As of 1/31/2024)
Outstanding Shares: 2,878,027,906 (As of 7/31/2024)
Stock Exchange: AQS


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 29, 2025